Literature DB >> 24491485

Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients.

E Mazzone1, R De Sanctis1, L Fanelli1, F Bianco1, M Main2, M van den Hauwe3, M Ash2, R de Vries4, J Fagoaga Mata5, K Schaefer6, A D'Amico7, G Colia7, C Palermo1, M Scoto2, A Mayhew8, M Eagle8, L Servais9, M Vigo5, A Febrer5, R Korinthenberg6, M Jeukens4, M de Viesser4, A Totoescu9, T Voit9, K Bushby8, F Muntoni2, N Goemans3, E Bertini7, M Pane1, E Mercuri10.   

Abstract

The aim of this prospective longitudinal multi centric study was to evaluate the correlation between the Hammersmith Functional Motor Scale and the 20 item version of the Motor Function Measure in non ambulant SMA children and adults at baseline and over a 12 month period. Seventy-four non-ambulant patients performed both measures at baseline and 49 also had an assessment 12 month later. At baseline the scores ranged between 0 and 40 on the Hammersmith Motor function Scale and between 3 and 45 on the Motor Function Measure 20. The correlation between the two scales was 0.733. The 12 month changes ranged between -11 and 4 for the Hammersmith and between -11 and 7 for the Motor Function Measure 20. The correlation between changes was 0.48. Our results suggest that both scales provide useful information although they appeared to work differently at the two extremes of the spectrum of abilities. The Hammersmith Motor Function Scale appeared to be more suitable in strong non ambulant patients, while the Motor Function Measures appeared to be more sensitive to capture activities and possible changes in the very weak patients, including more items capturing axial and upper limb activities. The choice of these measures in clinical trials should therefore depend on inclusion criteria and magnitude of expected changes.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Outcome measures; Spinal muscular atrophy

Mesh:

Year:  2014        PMID: 24491485     DOI: 10.1016/j.nmd.2014.01.003

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  12 in total

Review 1.  Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials.

Authors:  Pierre G Carlier; Benjamin Marty; Olivier Scheidegger; Paulo Loureiro de Sousa; Pierre-Yves Baudin; Eduard Snezhko; Dmitry Vlodavets
Journal:  J Neuromuscul Dis       Date:  2016-03-03

2.  MRI correlates of motoneuron loss in SMA.

Authors:  Alina Sprenger-Svačina; Johannes Haensch; Kilian Weiss; Nils Große Hokamp; David Maintz; Marc Schlamann; Gereon R Fink; Natalie Schloss; Kai Laukamp; Gilbert Wunderlich; Helmar C Lehmann; Thorsten Lichtenstein
Journal:  J Neurol       Date:  2022-10-01       Impact factor: 6.682

3.  Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies.

Authors:  Katherine G Meilleur; Minal S Jain; Linda S Hynan; Ching-Yi Shieh; Eunice Kim; Melissa Waite; Michelle McGuire; Courtney Fiorini; Allan M Glanzman; Marion Main; Kristy Rose; Tina Duong; Roxanna Bendixen; Melody M Linton; Irene C Arveson; Carmel Nichols; Kelly Yang; Kenneth H Fischbeck; Kathryn R Wagner; Kathryn North; Ami Mankodi; Christopher Grunseich; Elizabeth J Hartnett; Michaele Smith; Sandra Donkervoort; Alice Schindler; Angela Kokkinis; Meganne Leach; A Reghan Foley; James Collins; Francesco Muntoni; Anne Rutkowski; Carsten G Bönnemann
Journal:  Neuromuscul Disord       Date:  2014-09-28       Impact factor: 4.296

4.  Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.

Authors:  Xing Chen; Juliane Siebourg-Polster; Detlef Wolf; Christian Czech; Ulrike Bonati; Dirk Fischer; Omar Khwaja; Martin Strahm
Journal:  PLoS One       Date:  2017-01-25       Impact factor: 3.240

5.  Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool.

Authors:  Danielle Ramsey; Mariacristina Scoto; Anna Mayhew; Marion Main; Elena S Mazzone; Jacqueline Montes; Roberto de Sanctis; Sally Dunaway Young; Rachel Salazar; Allan M Glanzman; Amy Pasternak; Janet Quigley; Elizabeth Mirek; Tina Duong; Richard Gee; Matthew Civitello; Gihan Tennekoon; Marika Pane; Maria Carmela Pera; Kate Bushby; John Day; Basil T Darras; Darryl De Vivo; Richard Finkel; Eugenio Mercuri; Francesco Muntoni
Journal:  PLoS One       Date:  2017-02-21       Impact factor: 3.240

6.  Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

Authors:  Eugenio Mercuri; Richard Finkel; Jacqueline Montes; Elena S Mazzone; Maria Pia Sormani; Marion Main; Danielle Ramsey; Anna Mayhew; Allan M Glanzman; Sally Dunaway; Rachel Salazar; Amy Pasternak; Janet Quigley; Marika Pane; Maria Carmela Pera; Mariacristina Scoto; Sonia Messina; Maria Sframeli; Gian Luca Vita; Adele D'Amico; Marleen van den Hauwe; Serena Sivo; Nathalie Goemans; Petra Kaufmann; Basil T Darras; Enrico Bertini; Francesco Muntoni; Darryl C De Vivo
Journal:  Neuromuscul Disord       Date:  2015-12-03       Impact factor: 4.296

7.  Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study.

Authors:  Aurélie Chabanon; Andreea Mihaela Seferian; Aurore Daron; Yann Péréon; Claude Cances; Carole Vuillerot; Liesbeth De Waele; Jean-Marie Cuisset; Vincent Laugel; Ulrike Schara; Teresa Gidaro; Stéphanie Gilabert; Jean-Yves Hogrel; Pierre-Yves Baudin; Pierre Carlier; Emmanuel Fournier; Linda Pax Lowes; Nicole Hellbach; Timothy Seabrook; Elie Toledano; Mélanie Annoussamy; Laurent Servais
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

8.  Quantitative description of upper extremity function and activity of people with spinal muscular atrophy.

Authors:  Mariska M H P Janssen; Laura H C Peeters; Imelda J M de Groot
Journal:  J Neuroeng Rehabil       Date:  2020-09-11       Impact factor: 4.262

9.  Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests.

Authors:  Bart Bartels; Janke F de Groot; Laura E Habets; Camiel A Wijngaarde; Wendy Vink; Marloes Stam; Fay-Lynn Asselman; Ruben P A van Eijk; W Ludo van der Pol
Journal:  Orphanet J Rare Dis       Date:  2020-03-23       Impact factor: 4.123

10.  Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy.

Authors:  Kathrin Kizina; Benjamin Stolte; Andreas Totzeck; Saskia Bolz; Michael Fleischer; Christoph Mönninghoff; Nika Guberina; Denise Oldenburg; Michael Forsting; Christoph Kleinschnitz; Tim Hagenacker
Journal:  Front Neurol       Date:  2019-11-05       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.